2.24

7.18% 0.15

Pre-market: 2.23 -0.01 -0.45%

Opus Genetics Inc (IRD)

Overview News Price History Discussions Forecast

Opus Genetics Inc stock is traded at $2.24, with a volume of 365.86K. It is up +7.18% in the last 24 hours and up +3.23% over the past month. Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Previous Close:

$2.09

Open:

$2.09

24h Volume:

365.86K

Relative Volume:

0.83

Market Cap:

$154.48M

Revenue:

$8.38M

Net Income/Loss:

$-27.19M

P/E Ratio:

-2.055

EPS:

-1.09

Net Cash Flow:

$-13.59M

1W Performance:

+10.89%

1M Performance:

+3.23%

6M Performance:

+126.26%

1Y Performance:

+86.67%

1-Day Range:

$2.06

$2.29

1-Week Range:

$1.965

$2.29

52-Week Range:

$0.65

$2.37

Opus Genetics Inc Stock (IRD) Company Profile

Name

Opus Genetics Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

248-681-9815

Address

8 DAVIS DRIVE, DURHAM

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

IRD's Discussions on Twitter

Compare IRD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRD Opus Genetics Inc	2.24	144.14M	8.38M	-27.19M	-13.59M	-1.09
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-25-25	Initiated	Piper Sandler	Overweight
Oct-29-25	Initiated	Wedbush	Outperform
Oct-16-25	Initiated	Chardan Capital Markets	Buy
Apr-11-25	Initiated	Craig Hallum	Buy
Nov-13-24	Resumed	H.C. Wainwright	Buy

Opus Genetics Inc Stock (IRD) Latest News

03:51 AM

Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

03:51 AM

Dec 04, 2025

How Opus Genetics Inc. (R3X1) stock trades after rate cutsMarket Risk Analysis & Smart Allocation Stock Reports - Newser

Dec 04, 2025

Why Opus Genetics Inc. (R3X1) stock gets analyst attentionOptions Play & High Accuracy Trade Signal Alerts - Newser

Dec 04, 2025

Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings - MarketBeat

Dec 04, 2025

How Opus Genetics Inc. (R3X1) stock trades under stagflationAnalyst Downgrade & Fast Entry High Yield Stock Tips - Newser

Dec 04, 2025

Why institutional investors increase stakes in Opus Genetics Inc. (R3X1) stockMarket Growth Summary & Verified Entry Point Signals - Newser

Dec 04, 2025

Will Opus Genetics Inc. (R3X1) stock outperform small cap peers2025 Market WrapUp & Growth Focused Stock Reports - Newser

Dec 04, 2025

Brokers Issue Forecasts for Opus Genetics FY2025 Earnings - Defense World

Dec 04, 2025

Dec 03, 2025

Opus Genetics (NASDAQ:IRD) Upgraded to "Strong-Buy" at Brookline Capital Management - MarketBeat

Dec 03, 2025

Is Opus Genetics Inc. stock positioned well for digital economy - Newser

Dec 03, 2025

Why Opus Genetics Inc. stock remains on buy listsJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser

Dec 03, 2025

Brookline Capital Management Upgrades Opus Genetics (NASDAQ:IRD) to Strong-Buy - Defense World

Dec 03, 2025

Dec 02, 2025

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 02, 2025

Why Opus Genetics Inc. (R3X1) stock remains stable2025 Technical Patterns & Long-Term Growth Portfolio Plans - Newser

Dec 02, 2025

Will Opus Genetics Inc. (R3X1) stock test record highs in 2025Weekly Profit Summary & Long-Term Capital Growth Strategies - Newser

Dec 02, 2025

Dec 01, 2025

Brookline Capital Markets initiates Buy rating on Opus Genetics stock By Investing.com - Investing.com Canada

Dec 01, 2025

Nov 29, 2025

Opus Genetics, Inc.'s (NASDAQ:IRD) large institutional owners must be happy as stock continues to impress, up 12% over the past week - simplywall.st

Nov 29, 2025

Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT - Insider Monkey

Nov 29, 2025

Nov 28, 2025

Opus Genetics (NASDAQ:IRD) Earns Overweight Rating from Analysts at Piper Sandler - Defense World

Nov 28, 2025

Nov 27, 2025

12 Hot Penny Stocks to Invest in Right Now - Insider Monkey

Nov 27, 2025

Opus Genetics (NASDAQ:IRD) Coverage Initiated at Piper Sandler - MarketBeat

Nov 27, 2025

Nov 26, 2025

Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail

Nov 26, 2025

Nov 25, 2025

Piper Sandler Initiates Coverage on IRD with Overweight Rating a - GuruFocus

Nov 25, 2025

Opus Genetics gets 'overweight' rating as Piper Sandler initiates coverage - TradingView

Nov 25, 2025

Piper Sandler initiates coverage on Opus Genetics stock with Overweight rating - Investing.com Canada

Nov 25, 2025